Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening

The identification SMA affected infants via newborn screening presents an unprecedented opportunity for achievement of maximal therapeutic benefit through the administration of treatment pre-symptomatically. The recommendations provided here are intended to help formulate treatment guidelines for infants who test positive during the newborn screening process.